BMS Releases New Prefilled Injections of Orencia for Juvenile Idiopathic Arthritis Patients
News
Bristol-Myers Squibb recently announced that a new U.S. Food and Drug Administration (FDA)-approved formulation of Orencia (abatacept) is now available for patients with moderate to severely active polyarticular juvenile idiopathic arthritis. ... Read more